Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
ConditionOptic Neuritis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-50
SponsorOculis
About this trial
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Eligibility criteria
Qualifiers
Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss.
Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Privosegtor
- Methylprednisolone
- Placebo
Treatment groups
210 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov